Гипертрофическая кардиомиопатия: клинико-инструментальная характеристика, варианты клинического течения, прогноз и особенности медикаментозного лечения
Диссертация
В настоящее время наблюдается повсеместный рост числа зарегистрированных случаев этой патологии как за счёт внедрения в практику современных методов диагностики, так и, вероятно, в связи с истинным увеличением числа больных ГКМП. Частота выявления во многом зависит от наличия симптомов болезни, а, следовательно, от обращаемости пациентов в медицинские учреждения, от уровня медицинского… Читать ещё >
Список литературы
- Мухарлямов Н.М. Кардиомиопатии. М.: Медицина, 1990. — 288 с.
- Braunwald Е. (Ed). Heart Disease. A Textbook of Cardiovascular Medicine. Libbi Bonow Mann Zipes. Saunders Elsevier, 2008. — 2183 p.
- Goodwin J., Olsen E. (Eds.). Cardiomyopathies. Realisations and Expectations. -Springer-Verlag, 1993. 315 p.
- Brigden W. Uncommon myocardial disease. The non-coronary cardiomyopathies // Lancet. 1957. — Vol. 2. — P. 1179.
- Report of the WHO/ISFC Task Force on the Definition and Classification of Cardiomyopathies // Br. Heart J. 1980. — Vol. 44. — P. 672−673.
- Report of the 1995 WHO/ISFC Task Force on the Definition and Classification of Cardiomyopathies / Richardson P., McKenna W., Bristow M. et al. // Circulation. 1996. -Vol. 93. — P. 841−842.
- Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases / Elliott P., Andersson В., Arbustini E. et al. // Eur. Heart J. 2008. — Vol. 29. — P. 270−276.
- Teare D. Asymmetrical hypertrophy of the heart in young adults // Br. Heart J. -1958, — Vol. 20.-P. 1−18.
- A Report of the American Collage of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. // Eur. Heart J. 2003. — Vol. 24. — P. 1965−1991.
- Cardiomyopathies: Clinical Presentation, Differential Diagnosis, and Management / Ed. Shaver J. A. F.A., Davis Company, Philadelphia, 1988. — 288 p.
- Maron B.J., Roberts W.C. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy // Circulation. -1979.-Vol. 59. P. 689−706.
- Tanaka M., Fujiwara H., Onodera T. et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy // Circulation. 1987. — Vol. 75. — P. 1130−1139.
- Maron B.J., Bonow R.O., Cannon R.O. Ill et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy // N. Engl. J. Med. -1987.-Vol. 316.-P. 844−852.
- Cecchi F., Olivotto I., Gistri R. et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy // N. Engl. J. Med. 2003. — Vol. 349. -P.1027−1035.
- Fananapazir L., Tracy C. M., Leon M. B. et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy // Circulation. 1989. — Vol. 80. — P. 1259−1268.
- Maron B.J. Hypertrophic cardiomyopathy // Lancet. 1997. — Vol. 350. — P. 127−133.
- Wigle E.D., Sasson Z., Henderson M.A. et al. Hypertrophic cardiomyopathy. The importance of the of the site and the extent of hypertrophy. A review // Prog. Cardiovasc. Dis.- 1985. Vol. 28.-P. 1−83.
- Maron B. J., Peterson E. E., Maron M. S., Peterson J. E. Prevalence of hypertrophic cardiomyopathy in an outpatients population referred for echocardiographic study // Am. J. Cardiol. 1994. — Vol. 73. — P. 533−580.
- Maron B. J., Casey S. A., Poliac L. C. et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort// JAMA 1999. — Vol. 281. — P.650−655.
- Fay W. P., Taliercio C. P., Ilstrup D. M. et al. Natural history of hypertrophic cardiomyopathy in the elderly // J. Am. Coll. Cardiol. 1990. — Vol. 16. — P. 821−826.
- Maron B. J., Casey S. A., Hauser R. G., Aeppli D.M. Clinical course of hypertrophic cardiomyopathy with survival to advanced age // J. Am. Coll. Cardiol. 2003. -Vol. 42 (5). — P. 882−888.
- Monserrat L., Elliott P. M., Gimeno J. R. et al. Non-sustained ventricular tachicardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients // J. Am. Coll. Cardiol. 2003. — Vol. 42 (5). — P. 873−879.
- McKenna W. J., Deanfield J., Faruqui A. et al. Prognosis in hypertrophic cardiomyopathy. Role of age and clinical. Echocardiographic and hemodynamic features // Am. J. Cardiol. 1981. — Vol. 47. — P. 532−538.
- Maron B. J., Roberts W. C., Epstein S. E. Sudden death in hypertrophic cardiomyopathy. A profile of 78 patients // Circulation. 1982. — Vol. 65. — P. 1388−1394.
- Marian A. J., Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy // Circulation. 1995. — Vol. 92(5). — P. 1336−1347.
- Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy clinical conference. // JAMA. 1999. — Vol 281 (18). — P. 1746−1752.
- Solomon S. D. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene // J. Am. Coll. Cardiol. 1993. — Vol. 22(2). — P. 498−505.
- Watkins H. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations // J. Clin. Invest. 1992. — Vol. 90 (5). — P. 1666−1671.
- Elliott P., McKenna W. J. Hypertrophic cardiomyopathy // Lancet. 2004. — Vol. 363.-P. 1881−1891.
- Seidman J. G., Seidman С. E. The genetic basis for cardiomyopathy. From mutation identification to mechanistic paradigms // Cell. 2001. — Vol. 104. — P. 557−567.
- Фёдорова И.Ф. Клиника и течение обструктивной кардиомиопатии: Дис.канд. мед. наук. -М., 1984. 145 с.
- Хабарова Н. В. Оценка эффективности дифференцированного лечения гипертрофической кардиомиопатии на основании длительного проспективного наблюдения: Дис.. канд. мед. наук. 1994. — 178 с.
- Wigle Е. D., Rakowsky Н., Kimball В. P., Williams W. G. Hypertrophic cardiomyopathy. Clinical spectrum and treatment // Circulation. 1995. — Vol. 92. -P. 1680−1692.
- Sherrid M. V., Gunsburg D. Z., Sharma S. Medical treatment of hypertrophic cardiomyopathy // Curr. Cardiol. Rep. 2000. — Vol. 2 (2). — P. 148−153.
- McKenna W. J., Oakley С. M., Krikler D. M., Goodwin J. F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia // Br. Heart J. 1985. — Vol. 53. — P. 412−416.
- Rector Т., Kubo S. H., Cohn J. Patients self-assesment of their congestive heart failure: contact, reliability and validity of a new measure the Minnesota Living With Heart Failure Questionnaire // Heart Failure. — 1987. — Vol. 3. — P. 198−209.
- Liouville H. Retrecissement cardiaque sous aortique // Gazette Med. Paris. 1869. -Vol. 24.-P. 161−165.
- Braunwald E., Lambrew C., Rockoff S. Idiopathic hypertrophic subaorthic stenosis: a description of the disease // Circulation. 1964. — Vol. IV. — P. 3−119.
- Frank S., Braunwald E. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients // Circulation. 1968. — Vol. 37. — P. 759−788.
- Clark С. E, Henry W. L., Epstein S. E. Familial prevalence and genetic transmission of idiopathic hypertrophic subaortic stenosis//N. Engl. J. Med 1973 — Vol. 289. — P. 709−714.
- Hypertrophic cardiomyopathy mutation database Электронный ресурс. // 2009. -Доступ: http: //genetics.med.harvard.edu/~seidman/cg3.
- Bonne G., Carrier L., Richard P. et al. Familial hypertrophic cardiomyopathy: from mutations to functional defects // Circ. Res. 1998. — Vol. 83. — P. 580−593.
- Jarcho J. A., McKenna W., Pare J. A. et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14ql// N. Engl. J. Med. 1989.- Vol. 321. — P. 1372−1378.
- Ilejtmancik J. F., Brink P. A., Towbin J. et al. Localization of gene for familial hypertrophic cardiomyopathy to chromosome 14ql in a diverse US population // Circulation. 1991.-Vol. 83. P. 1592−1597.
- Geisterfer-Lowrance A. A., Kass S., Tanigawa G. et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation // Cell. 1990. — Vol. 62. — P. 999−1006.
- Solomon S. D., Wolff S., Watkins H. et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene // J. Am. Coll. Cardiol. 1993. — Vol. 22. — P. 498−505.
- Jaenicke Т., Diederich K. W., Haas W. et al. The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product // Genomics. -1990.-Vol. 8.-P. 194−206.
- Liew C. C., Sole M. J., Yamauchi-Takihara K. et al. Complete sequence and organization of the human cardiac beta-myosin heavy chain gene // Nucleic. Acids Res. -1990.-Vol. 18.-P. 3647−3651.
- Wendel B., Reinhard R., Wachtendorf U. et al. The human (3 myosin heavy chain gene: sequence diversity and functional characteristics of the Protein // J. Cell Bioch. -2000.-Vol. 79.-P. 566−575.
- Watkins H., Rosenzweig A., Hwang D. S. et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy // N. Engl. J. Med. 1992,-Vol. 326.-P. 1108−1114.
- Fung D. C., Yu B., Littlejohn T. et al. An online locus-specific mutation database for familial hypertrophic cardiomyopathy // Hum. Mutat. 1999. — Vol. 14. — P. 326−332.
- Abchee A., Marian A. J. et al. Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy // J. Investig. Med. 1997. — Vol. 45 (4). — P. 191−196.
- Watkins H. Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy// Am. J. Hum. Genet. 1993. — Vol. 53 (6). -P.1180−1185.
- Watkins H., Seidman C. E., MacRae C., Seidman J. G., McKenna W. Progress in familial hypertrophic cardiomyopathy: molecular genetic analyses in the original family studied by Teare // Br. Heart J. 1992. — Vol. 67. — P. 34−38.
- Woo A., Rakowski H., Liew J. C. et al. Mutations of the beta myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis // Heart. -2003.-Vol. 89 (10).-P. 1179−1185.
- Marian A. J., Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy // Circulation. 1995. — Vol. 92. P. 1336−1347.
- Marian A. J. Sudden cardiac death in patients with hypertrophic cardiomyopathy: from bench to bedside with an emphasis on genetic markers // Clin. Cardiol. 1995. -Vol. 18.-P. 189−198.
- Fananapazir L., Epstein N. D. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations // Circulation. 1994. — Vol. 89. — P. 22−32.
- Anan R., Greve G, Thierfelder L. et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy // J. Clin. Invest. 1994. — Vol. 93. — P. 280−285.
- Jeschke B., Uhl K., Weist B. et al. A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes // Hum. Genet. 1998. — Vol. 102. — P. 299−304.
- Mohiddin S. A., Begley D. A., McLam E. et al Utility of genetic screening in hypertrophic cardiomyopathy: prevalence and significance of novel and double (homozygous and heterozygous) beta-myosin mutations // Genet. Test. 2003. -Vol. 7(1).-P. 21−27.
- Atiga W. L., Fananapazir L., McAreavey D. et al. Temporal Repolarization Lability in Hypertrophic Cardiomyopathy Caused by beta-Myosin Heavy-Chain Gene Mutations // Circulation. 2000. — Vol. 101.-P. 1237−1242.
- Blair E., Redwood C., de Jesus Oliveira M. et al. Mutations of the light meromyosin domain of the beta-myosin heavy chain rod in hypertrophic cardiomyopathy // Circ. Res. -2002. Vol. 90 (3). — P. 263−269.
- Havndrup O., Bundgaard H., Andersen P. S. et al. Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations // Cardiovasc. Res. 2003. — Vol. 57 (2). — P. 347−357.
- Tajsharghi H., Thornell L. E., Lindberg C. et al. Myosin storage myopathy associated with a heterozygous missense mutation in MYH7 // Ann. Neurol. 2003. — Vol. 54 (4). -P. 494−500.
- Gruver E. J., Fatkin D., Dodds A. et al. Familiar hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation // Am. J. Cardiol. 1999.- P. 13H-18H.
- Gautel M., Zuffardi O., Freiburg A., Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? // Emb. J. 1995.-Vol. 14.-P. 1952−1960.
- Watkins Ft., Conner D., Thierfelder L. et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy // Nat. Genet. 1995.-Vol. 11.-P. 434−437.
- Niimura H., Bachinski L.L., Sangwatanaroj S. et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy // Engl. J. Med. 1998. — Vol. 338. — P. 1248−1257.
- Charron P., Dubourg O., Desnos M. et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene // Circulation. 1998. — Vol. 97. — P. 2230−2236.
- Bouhour J. B., Schwartz K., Desnos M., Komajda M. Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy // Heart. 2002. -Vol. 88 (2).-P. 153−157.
- Thierfelder L., Watkins H., MacRae C. et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere // Cell. 1994.-Vol. 77.-P. 701−712.
- Hengstenberg C., Charron P., Isnard R. et al. Demonstration of a fifth locus implicated in familial hypertrophic cardiomyopathies // Arch. Mal. Coeur. Vaiss. 1994. — Vol. 87. -P.1655−1662.
- Watkins H., McKenna W. J., Thierfelder L. et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy // N. Engl. J. Med. -1995. Vol. 332. — P. 1058−1064.
- Hanson E. L., Jakobs P. M., Keegan H. et al. Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy // J. Card. Fail. 2002. — Vol. 8 (1). — P. 28−32.
- Fujino N., Shimizu M., Ino H et al. A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy // Am. J. Cardiol. 2002. — Vol. 89 (1). — P. 29−33.
- Varnava A., Baboonian C., Davison F. et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy // Heart. 1999. — Vol. 82. — P. 621−624.
- MacLeod A. R., Gooding C. Human hTM alpha gene: expression in muscle and nonmuscle tissue // Mol. Cell. Biol. 1988. — Vol. 8. — P. 433−440.
- Thierfelder L., MacRae C., Watkins H. et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2 // Proc. Natl. Acad. Sci. USA. 1993. — Vol. 90. -P. 70−74.
- Van Driest S. L., Will M. L., Atkins D .L., Ackerman M. J. A novel TPM1 mutation in a family with hypertrophic cardiomyopathy and sudden cardiac death in childhood // Am. J. Cardiol. 2002. — Vol. 90(10). — P. 1123−1127.
- MacGeoch C., Barton P.J., Vallins W. J. et al. The human cardiac troponin I locus: assignment to chromosome 19pl3.2−19ql3.2//Hum. Genet. 1991. — Vol. 88.-P. 101−104
- Kimura A, Harada H, Park J. E. et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy // Nat. Genet. 1997. — Vol. 16. — P. 379−382
- Morner S., Richard P., Kazzam E. et al. Deletion in the cardiac troponin I gene in a family from northern Sweden with hypertrophic cardiomyopathy // J. Mol. Cell. Cardiol. -2000.-Vol. 32.-P. 521−525.
- Mogensen J., Kubo T., Duque M. et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations // J. Clin. Invest. 2003. -Vol. Ill (2).-P. 209−216.
- Poetter K., Jiang H., Hassanzadeh S. et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle // Nat. Genet. 1996. — Vol. 13. — P. 63−69.
- Kabaeva Z. T., Perrot A., Wolter B. et al. Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy // Eur. J. Hum. Genet. 2002. — Vol. 10 (11). P. 741−748.
- Mogensen J., Klausen I.C., Pedersen A.K. et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy // J. Clin. Invest. 1999. — Vol. 103-P.39−43.
- Olson T. M., Michels V. V., Thibodeau S. N. et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure // Science. 1998. — Vol. 280. P. 750−752.
- Satoh M., Takahashi M., Sakamoto T. et al. A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene // Biochem. Biophys. Res. Commun. 1999. — Vol. 262. — P. 411−417.
- Hackman J. P., Vihola A. K., Udd A. B. The role of titin in muscular disorders // Ann. Med. 2003. — Vol. 35 (6). P. 434−441.
- Cherry J. M., Green M. S. Familiar cardiomyopathy: a new autosomal dominant form // Clin. Invest. Med. 1986. — Vol. 9. — B31.
- MacRae C. A., Ghaisas N., Kass S. et al. Familial Hypertrophic cardiomyo-pathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3 // J. Clin. Invest. 1995. — Vol. 96. — P. 1216−1220.
- Gollob M. H., Green M.S., Tang A. S., Roberts R. PRKAG2 cardiac syndrome: familiar ventricular preexcitation, conduction system disease, and cardiac hypertrophy // Curr. Opin. Cardiol. 2002. — Vol. 17. — P. 229−234.
- Goto Y., Nonaka I., Horai S. A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) // Biochim. Biophys. Acta. 1991. — Vol. 1097. — P. 238−240.
- Morten K. J., Cooper J. M., Brown G. K. et al. A new point mutation associated with mitochondrial encephalomyopathy // Hum. Mol. Genet. 1993. — Vol. 2. — P. 2081−2087.
- Holmgren D., Wahlander II., Eriksson B. O. et al. Cardiomyopathy in children with mitochondrial disease- clinical course and cardiological findings // Eur. Heart J. 2003. -Vol. 24(3).-P. 221−224.
- Marin-Garcia J., Goldenthal M. J., Filiano J. J. Cardiomyopathy associated with neurologic disorders and mitochondrial phenotype // J. Child. Neurol. 2002. — Vol. 17 (10).-P. 759−765.
- Phillips M. F., Harper P. S. Cardiac disease in myotonic dystrophy // Cardiovasc. Res. 1997. — Vol. 33. P. 13−22.
- Palau F. Friedreich’s ataxia and frataxin: molecular genetics, evolution and pathogenesis //Int. J. Mol. Med. -2001. Vol. 7. — P. 581−589.
- Hoffmann B., Schmidt-Traub H., Perrot A. et al. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy // Flum. Mutat. 2001. — Vol. 17. -P. 524.
- Niimura H., Patton K. K., McKenna W. J. et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly // Circulation. 2002. — Vol. 105. — P. 446 451.
- Hayashi T., Arimura T., Ueda K. et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy // Biochem. Biophys. Res. Commun. 2004. — Vol. 313 (l).-P. 178−184.
- Marin-Garcia J., Goldenthal M.J., Filiano J. J. Cardiomyopathy associated with neurologic disorders and mitochondrial phenotype // J. Child. Neurol. 2002. — Vol. 17 (10).-P. 759−765.
- Geier C., Perrot A., Ozcelik C. et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy //Circulation. 2003. — Vol. 107 (10). -P. 1390−1395.
- Erdmann J., Daehmlow S., Wischke S. et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy // Clin. Genet. 2003. -Vol.64 (4).-P. 339−349.
- Keller D. I., Carrier L., Schwarts K. Genetics of familiar cardiomyopathies and arrhythmias // Swiss Med. Wkly. 2002. — Vol. 132. — P. 401−407.
- Turner L. F., Kaddoura S., Harrington D. et al. Mitochondrial DNA in idiopathic cardiomyopathy // Eur. Heart J. 1998. — Vol. 19. — P. 1725−1729.
- Jaaskelainen P., Miettinen R., Karkkainen P. et al. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes // Ann. Med. 2004, — Vol. 36 (1). — P. 23−32.
- Van Driest S. L., Ellsworth E .G., Ommen S. R. et al. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy // Circulation. 2003.- Vol. 108 (4). P. 445−451.
- Ko Y. L., Teng M. S., Tang T. К. et al. Genetic heterogeneity for familial hypertrophic cardiomyopathy in Chinese: analysis of six Chinese kindreds // Chin. Med. J. (Engl). 1998. — Vol. 111. — P. 416−421.
- Alders M., Jongbloed R., Deelen W. et. al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands // Eur. Heart J. 2003. — Vol. 24 (20). — P. 1848−1853.
- Morner S., Richard P., Kazzam E. et. al. Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden // J. Mol. Cell. Cardiol. 2003. -Vol.35 (7).-P. 841−849.
- Бочков H. П. Клиническая генетика. M.: Медицина, 1997. — С. 212−237.
- Селезнёв Д. М. Спектр и фенотипические проявления мутаций в гене тяжелой цепи сердечного бета-миозина у российских пациентов с гипертрофической кардиомиопатией- Дис.. канд. мед. наук. Москва, 2006. 112 с.
- Sambrook J., Fritsch E.F., Maniatis Т. / Molecular Cloning. 2nd Ed. Cold. Spring Harbo, 1989.
- Тавадов Г. Т. Этнология. Учебник для ВУЗов. М., Проект, 2002. — С. 147−163.
- Spirito P., Rapezzi С., Bellone P. et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis // Circulation. 1999. — Vol. 99. — P. 2132−2137.
- Fananapazir L., Dalakas M. C., Cyran F. et. al. Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy // Proc. Natl. Acad. Sci. USA. 1993. — Vol. 90. — P. 3993−3997.
- Suzuki J., Shimamoto R., Nishikawa J. et. al. Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: A long term analysis with nuclear magnetic resonance imaging // J. Am. Coll. Cardiol. 1999. — Vol. 33. — P. 146−151.
- Maron B. J. Hypertrophic cardiomyopathy: a systematic review // JAMA. 2002. -Vol. 287.-P. 1308−1320.
- Factor S. M., Butany J., Sole M. J. et al. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium in patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol.-1991.-Vol. 17.-P. 1343−1351.
- Davies M. J., Pomerance A., Teare R. D. Pathological features of hypertrophic obstructive cardiomyopathy // J. Clin. Pathol. 1974. — Vol. 27. — P. 529−535.
- Davies M. J. The current status of myocardial disarray in hypertrophic cardiomyopathy//Br. Heart J. 1984.-Vol. 51.-P. 361−363.
- Klues L. G., Leuner C., Kuhn H. Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise // J. Am. Coll. Cardiol. 1992. — Vol. 19. — P. 527−533.
- Kizilbash A. M., Heinle S. K., Grayburn P. A. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy // Circulation. 1998. — Vol. 97. — P. 461−466.
- Klues H., Roberts W., Maron B. Morphologic determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy // Circulation. 1993. — Vol. 87. — P. 1570−1579.
- Sherrid M., Chu C., Delia E. et al. An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 1993. — Vol. 22. -P. 816−825.
- Мухарлямов H. M., Затушевский И. Ф., Дорофеева 3. 3. Идиопатический гипертрофический субаортальный стеноз // Тер. Архив. 1980. — № 7. — С. 18−25.
- Sherrid M.V., Gunsburg D. Z., Moldenhauer S. et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy // J. Am. Coll. Cardiol.-2000.-Vol. 36.-P. 1344−1354.
- Shah P., Taylor R., Wong M. Abnormal mitral coaptation in hypertrophic obstructive cardiomyopathy // Am. J. Cardiol. 1981. — Vol. 48. — P. 258−262.
- Wigle E. Cardiomyopathy. The diagnosis of hypertrophic cardiomyopathy // Heart. 2001. — Vol. 86. — P. 709−714.
- Choudhury L., Mahrhoidt II., Wagner A. et al. Myocardial scarring in asyptomatic or midly symptomatic patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. -2002.-Vol. 40.-P. 2156−2164.
- Cannon R., Rosing D., Maron B. et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy contribution of inadequate vasodilator reserve and elevated ventricular filling pressures // Circulation. 1985. — Vol. 71. — P. 234−243.
- Frenneaux M., Porter A., Caforio A. et al. Determinants of exercise capacity in hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 1989. — Vol. 13. — P. 1521−1526.
- Briguori С., Betocchi S., Romano M. et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function // Am. J. Cardiol. 1999. -Vol. 84.-P. 309−315.
- Maron В., Olivotto I., Betocchi S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy // N. Engl. J. Med. -2003.-Vol. 348.-P. 295−303.
- Briguori C., Betocchi S., Romano M. et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function // Am. J. Cardiol. 1999. -Vol. 84.-P. 309−315.
- Чигинева B.B., Мазур H. А. Нарушения диастолической функции левого желудочка при гипертрофической кардиомиопатии // В кн. «Диастолическая дисфункция миокарда. Москва, 2001. — С. 54−66.
- Lele S., Thomson Н., Seo Н. et al. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics // Circulation. 1995. — Vol. 92. — P. 2886−2894.
- Betocchi S., Hess O., Losi M. et al. Regional left ventricular mechanics in hypertrophic cardiomyopathy // Circulation. 1993. — Vol. 88. — P. 2206−2214.
- Spirito P., Maron B. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. -1990.-Vol. 15.-P. 808−813.
- Brutsaert D. L., Sys S. U, Gillebert Т. C. Diastolic Failure: Pathophysiology and Therapeutic Implication // J. Am. Coll. Cardiol. 1993. — Vol. 22. — P. 318−325.
- Sanderson J. E., Gibson D. G., Brown D. J. et al. Left ventricular filling in hypertrophic cardiomyopathy, an angiographic study // Br. Heart J. 1977. — Vol. 39. -P. 661−670.
- Robinson K., Frenneaux M., Stockins B. et al. Atrial fibrillation in hypertrophic cardiomyopathy. A longitudinal study//J. Am. Coll. Cardiol.-1990.-Vol. 15.-P.1279−1285.
- Olivotto I., Cecchi F., Casey S. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy // Circulation. 2001. — Vol. 104. — P. 2517−2524.
- Maron B., Spirito P., Green K. et al. Noninvasive assessment of left ventricular diastolic function by pulsed doppler echocardiography in patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 1987. — Vol. 10. — P. 733−742.
- Matsumura Y., Elliot P., Virdee M. et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity // Heart. 2002. — Vol. 87. — P. 247−251.
- Sutton S. J., Lie J. T., Anderson K. K. et al, Hystopathological specifity of obstructive hypertrophic cardiomyopathy. Myocardial fibre dissaray and myocardial fibrosis // Br. Heart J. 1980. — Vol. 44. — P. 433.
- Haley J. H., Miller T. D. Myocardial ischemia on tallium scintigraphy in hypertrophic cardiomyopathy: predictor of sudden cardiac death // Circulation. 2001. -Vol.104 (13).-P. 71−81.
- Spirito P., Seidman C. E., McKenna W. et al. The management of hypertrophic cardiomyopathy // N. Engl. J. Med. 1997. — Vol. 336. — P. 775−785.
- Garcia M. J., Thomas J. D., Klein A. L. New Doppler applications for the study of diastolic function // J. Am. Coll. Cardiol. 1998. — Vol. 32. — P. 865−875.
- Appleton C. P., Hatle L. K. The natural history of left ventricular filling abnomialities: assessment by two-dimension and Doppler echocardiography // Echocardiography. 1992. -Vol. 9.-P. 437−445.
- Ishida Y., Meisner J. S., Tsujioka K. et al. Left ventricular filling dynamics: influence of left ventricular relaxation and left atrial pressure // Circulation .-1986 .- Vol. 74 -P. 187−196
- Sohn D. W., Chai I. H., Lee D. J. et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function // J. Am. Coll. Cardiol. 1997. — Vol. 30. — P. 760−768.
- Gardin J., Dabstani A., Glasgow G. et al. Echocardiography and Doppler flow observations in obstructed and nonobstructed hypertrophic cardiomyopathy // Am. J. Cardiol. -1985.-Vol. 56.-P. 614−621.
- Severino S., Caso P., Galderisi M. et al. Use of pulsed Doppler tissue imaging to assess regional left ventricular diastolic dysfunction in hypertrophic cardiomyopathy // Am. J. Cardiol. 1998. — Vol. 82. — P. 1394−1398.
- Briguori C., Hatle L. K., Losi M. A. et al. Noninvasive evalution left ventricular diastolic function in hypertrophic cardiomyopathy//Am. J. Cardiol. 1998.-Vol. 81.-P. 180−187.
- Nagueh S. F., Lakkis N. M., Middleton К. J. et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy // Circulation. 1999. -Vol. 99.-P. 254−261.
- McMahon C., Nagueh S. F., Pignatelli R. H. Characterization of left ventricular diastolic function by Doppler tissue imaging and clinical status in children with hypertrophic cardiomyopathy // Circulation. 2004. — Vol. 109. — P. 1756−1762.
- Ш. Беленков Ю. H., Терновой С. К. Функциональная диагностика сердечнососудистых заболеваний // М.: ГЭОТФР-Медиа- 2007.
- Ho C. Y., Sweitzer N. K., McDonough B. et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy // Circulation. 2002. — Vol. 105. — P. 2997- 3004.
- Шиллер Н., Осипов М. А. Клиническая эхокардиография. М. 1993. — 347 с.
- Yamamoto К., Redfield М., Nishimura R. Analysis of left ventricular diastolic function // Heart. 1996. — Vol. 75 (suppl 2). — P. 27—35.
- Nash P., Lin S., Armstrong G. Transthoracic echocardiography / Eds. Griffin В., Topol E. Manual of cardiovascular medicine.- Philadelphia, Lippincott Williams & Wilkins, 2004. — 794 p.
- Maron B. J., Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy //Am. J. Cardiol. 1998.-Vol. 81 (11).-P. 1339−1344.
- Сторожаков Г. И., Кисляк О. А., Селиванов А. И. Гипертрофическая кардиомиопатия // Кардиология. 1995. — Том 35, № 6. — С. 78−85.
- Шапошник И. И., Богданов Д. В. Гипертрофическая кардиомиопатия. М.: Медпрактика-М, 2008. 127 с.
- Беленков Ю. Н., Привалова Е. В., Каплунова В. Ю., Фомин А. А. Гипертрофическая кардиомиопатия, особенности течения при длительном наблюдении // Тер. Архив. 2008.-№ 8. — С. 18−25.
- Коровина Е. П., Моисеев В. С. Недостаточность кровообращения при гипертрофической кардиомиопатии // Кардиология. 1997. — Том 37, № 11. — С. 31−35.
- Thaman R., Gimeno J. R., Murphy R. T. et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy // Heart. 2005. — Vol. 91 (7). — P. 920−925
- Maron B. J. Myocardial disorganization in hypertroyhic cardiomyopathy. Another point of view // Br. Heart J. -1983. Vol. 50. — P. 1−3.
- Maron B. J., Venter J., Kapur S. Disproportionate ventricular septal thichening in the developing normal human heart // Circulation. 1978. — Vol. 57. — P. 520−526.
- Nishimura K., Nosaka H. Another possible mechanism of angina in hypertrophic cardiomyopathy // Circulation. 1983. — Vol. 68. — P. 111−162.
- Maron В., Wolfson J., Epstein S. et al. Intramural «small vessels» coronary artery disease in hypertrophic cardiomyopathy //J. Am. Coll. Cardiol 1986 — Vol. 8 -P. 545−551
- Tanaka M., Fujinara H., Onodera T. et al. Qualitative analysis of myocardial fibrosis in normal, hypertensive hearts and hypertrophic cardiomyopathy // Br. Heart J. -1986.-Vol. 55.-P. 575.
- Mohri ML, Takeshita A. Coronary microvascular disease in humans // Jpn. Heart J. 1999. — Vol. 40. — P. 97−108.
- Aksaka T., Yoshikawa J., Yoshida K. et al. Phasic coronary flow characteristics in patientswith hypertrophic cardiomyopathy: a study by coronary Doppler catheter // J. Am. Soc. Echocardiogr. 1994. — Vol. 7. — P. 9−19.
- Mandinov L., Eberli F., Seiler S. et al. Diastolic heart failure // Cardiovasc. Res. 2000. — Vol. 45. — P. 813−825.
- Li S. T., Tack C. J., Fananapazir L. et al. Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 2000. -Vol. 35.-P. 1867−1873.
- Giannitsis E., Haase H., Schmucker G. et al. Apical hypertrophic cardiomyopathy of the Japanese type coexistent with coronary muscle bridge. A case report and review // Jpn. Heart J. -1997. Vol. 38 (5). — P. 741−748.
- Mochiddin S. A., Begley D., Shih J. et al. Myocardial bridging does not predict sudden death in patients with hypertrophic cardiomyopathy but is assotiated with more severe cardiac disease // J. Am. Coll. Cardiol. 2000. — Vol. 36 (7). — P. 2270−2278.
- Yetman A. T., McCrindle B. W., McDonald C. et al. Myocardial bridging in patient with hypertrophic cardiomyopathy a risk factor for sudden death. // N. Engl. J. Med. — 1998. -Vol. 339 (17).-P. 1201−1209.
- Pichard A. D. Septal perforator compression in idiopathic hypertrophic cardiomyopathy // Am. J. Cardiol. 1977. — Vol. 40. — P. 310−314.
- Maron B. J., Epstein S. E., Roberts W. C. et al. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the coronaiy arteries // Am. J. Cardiol. 1979. — Vol. 43. — P. 1086.
- Camici P.G., Cecchi F., Gistri R. et al. Dipiridamole-iducad subendocardial underperfusion in hypertrophic cardiomyopathy assesedby positron-emission tomography // Coron. Artery Dis. 1991. — Vol. 2. — P. 837−841.
- Cannon R. O., Dilsizian V., Epstein S. E. et al. Myocardial methabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities hypertrophic cardiomyopathy // Circulation. 1991. — Vol. 83. — P. 1660−1667.
- Tamadura E., Kudon T., Matsumory A. et al. Impairment of BMIPP uptake preceds abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy // J. Nucl. Med. 1998. — Vol. 39 (3). — P. 390−306.
- Кушаковкий M.C. Идиопатические кардиомиопатии. С-П.: Фолиант, 1998. 312 с.
- Пирцхалаишвили Н. А. Внутисердечная гемодинамика и состояние коронарного кровотока у больных гипертрофической кардиомиопатией: Дис.. канд. мед. наук, М. — 1992. 150 с.
- Pasternac A., Noble J., Streulens Y. et al. Pathophisiology of chest pain in pathients with cardiomyopathies and normal coronary arteries // Circulation. 1982. — Vol. 65. — P. 778.
- Marcus M. L., Doty D. В., Hiratska L. W. et al. Decreased coronary reserve. A mechanism of angina pectoris in patients with subaortic stenosis and normal coronary arteries // N.Engl. J.Med.- 1982.-Vol. 307.-P. 1362.
- Aksaka T., Yoshiawa J., Yoshida K. et al. Phasic coronary flow caracteristics in patients with hypertrophic cariomyopathy: a study by coronary Doppler catheter // J. Am. Soc. Echocardiogr.- 1994. -Vol. 7 (l).-P. 9−19.
- Choudhury L., Rosen S. D., Patel D. et al. Coronary vasodiator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography // Eur. Heart J.-1999.-Vol. 18.-P. 108−116.
- Капелько В.И. Внеклеточный матрикс миокарда и его изменения при заболеваниях сердца // Кардиология. 2000. — № 9. — Р. 78−90.
- Roberts R. Molecular genetics: therapy or terror? // Circulation. 1994. — Vol. 89. -P. 499−502.
- Сергиенко В. Б. Однофотонная эмиссионная компьютерная томография. Опыт клинического применения: Дис. .докт. мед. наук, М. 1984. — 297 с.
- Самойленко JI.E. Перфузионная сцинтиграфия миокарда в клинической кардиологии: Дис. .докт. мед. наук, М. 1998. — 392 с.
- Yamada M., Elliot P. M., Kaski J. C. et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome // Eur. Heart J. 1998. — Vol. 19. — P. 500−507.
- Pitcher D., Mainwright R., Maisey M. et al. Assessment of chest pain hypertrophic cardiomyopathy using exercise thallium-201 myocardial scintigraphy // Br. Heart J. -1980.-Vol. 44.-P. 650−656.
- Li S. Т., Tack С. J., Fananapazir L. et al. Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 2000. -Vol. 35.-P. 1867−1873.
- СГ Gara P. Т., Bonow R. O., Maron B. J. et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy assessment with thallium-201 emission computed tomography // Circulation. 1987. — Vol. 76. — P. 1214−1223.
- Аверкина H.B. Влияние медикаментозной терапии на клинико-гемодинамические показатели и перфузию миокарда у больных гипертрофической кардиомиопатией: Дисс.. канд. мед. наук, М. 2002. — 121 с.
- Morishita S., Kondo Y., Nomura M. et al. Impaired retention of technetium99"1-tetrofosmin in hypertrophic cardiomyopathy //Am. J. Cardiol 2001 — Vol. 87 — P. 743−747
- Kagaya Y., Ishide N., Takeyama D. et al. Differences in myocardial fluoro-18−2-deoxyglucose uptake in round versus older patients with hypertrophic cardiomyopathy // Am. J. Cardiol. 1992. — Vol. 20. — P. 242−246.
- Sugihara H., Toniguchi Y., Matsumori A. et al. Reserve redistridution of Tc-99m-tetrofosmin in exercise myocardial SPECT in patients with hypertrophic cardiomyopathy // Ann. Nucl. Med. 1998. — Vol. 12 (5). — P. 287−292.
- Дубов П. Б., Фофанова Т. В., Остроумов Е. Н. Миокардиальный резерв перфузии и гипертрофия миокарда у больных гипертонической болезнью и «немой» ишемией миокарда // Кардиология. 1994. — № 6. — С. 126−128.
- Wieneke Н., Zander С. Non-invasive characterization of cardiac microvascular disease by nuclear medicine using single-proton emission tomography // Herz. 1999. -Vol.24 (7).-P. 515−521.
- McKenna W. J., England D., Doi Y. et al. Arrhythmia in hypertrophic cardiomyopathy. Influence on prognosis//Br. Heart J. 1981.-Vol. 46.-P. 168−172.
- Мамаева Г. И., Волгин Е. Г. Характер нарушений ритма сердца и проводимости у больных различными формами гипертрофической кардиомиопатии // «Современные методы лечения ССЗ»: сб. науч. тр. Л., 1991. — С. 138−143.
- Хирманов В. Н., Трешкур Т. В., Тюрина Т. В. и др. Электрокардиографические методы в диагностике, выборе метода и тактики лечения гипертрофической кардиомиопатии // Progress in Biomedical Research. С-Пб., 1991. — С. 138−153.
- Antzelevitch С. Molecular genetics of arrhythmias and cardiovascular conditions associated with arrhythmias//.!. Cardiovasc. Electrophysiol.-2003.-Vol. 14. P. 1259−1272.
- Wolf C.M., Moskowitz I.P., Arno S. Et al. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia // Proc. Natl. Acad. Sci. USA.-2005.-Vol. 102.-P. 18 123−18 128.
- Tomaselli G.F., Marban E. Electrophysiological remodeling in hypertrophy and heart failure // Cardiovasc. Res. 1999- 42: 270−283.
- Maron B. J., Savage D. D., Wolfson J. K. et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am. J. Cardiol. 1981. — Vol. 48.- P. 252−257.
- McKenna W. J., Chetty S., Oakley С. M. et al. Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocariographic assessment with and without beta adrenergic blocking therapy // Am. J. Cardiol. 1980. — Vol. 45. — P. 1−5.
- McKenna W. J., Franklin R. S., Nihoyannopoulis P. et al. Arrhytmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol.- 1988.-Vol. 11.-P. 147−153.
- Abadag A. S., Casey S. A., Kuskowsky M. A. et al. Spestrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 2005. — Vol. 45. — P. 697−704.
- Robinson K., Frenneaux M., Stockins B. et al. Atrial fibrillation in hypertrophic cardiomyopathy: longitudinal study // Am. J. Cardiol. 1990. — Vol. 15. — P. 1279−1364.
- Waxman M. B. Wald R. W., Cameron D. Interactions between the automatic nervous system and tachycardias in man // Cardiol. Clin. 1983. — Vol. 1. — P. 143−185.
- Gwathmey J. K., Warren S. E., Briggs G. M., et al. Diastolic disfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole // J.Clin. Invest. 1991.-Vol. 87.-P. 1023−1031.
- Kawai C., Yui Y., Hoshino T. et al. Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study // J. Am. Coll. Cardiol. 1983. -Vol. 2. P. 834−844.
- Brush J. E., Eisenhofer G., Garty M. et al. Cardiac norepinephrine kineics in hypertrophic cardiomyopathy // Circulation. 1989. — Vol. 79. — P. 836−844.
- Golf S., Myhre E., Abdelnoor M. et al. Hypertrophic cardiomyopathy characterized by beta-adrenoreceptor density, relative amount of beta-adrenoreceptor subtypes, and adenilate cyclase activity // Cardiovasc. Res. 1985. — Vol. 19. — P. 693−699.
- Choudhury L., Guzzetti S., Lefrou D.C. et al. Myocardial beta- adrenoceptors and left ventricular function in hypertrophic cardiomyopathy // Heart. 1996. -Vol. 75. — P. 50−54.
- Counihan J., Lu Fei, Bashir Y. et al. Assessment of heart rate variability in hypertrophic cardiomyopathy. Association with clinical and prognostic features // Circulation. 1993. — Vol. 88. — P. 1682−1690.
- Ajiki K., Murakawa Y., Yanagisawa-Miwa A. et al. Autonomic nervous system activity in idiopathic dilated and hypertrophic cardiomiopathy // Am. J. Cardiol. 1993. -Vol. 71.-P. 1316−1320.
- Tanabe T., Iwamoto T., Fusegawa Y. et al. Alteration of sympathovagal balance in patients with hypertrophic and dilated cardiomyopathies assessed by spectral analysis of RR interval variability // Eur. Heart J. 1995. — Vol. 16. — P. 799−807.
- Lu Fei, Stade A. K., Prasad K. et al. Is there increased sympathetic activity in patients with hypertrophic cardiomiopathy? // J. Am. Coll. Cardiol. 1995. — Vol. 26. — P. 472−480.
- Bonaduce D., Petretta M., Betocchi S. et al. Heart rate variability in patient with hypertrophic cardiomyopathy: association with clinical and echocardiographic features // Am. Heart J. 1997. — Vol. 134. — P. 165−172.
- Limbruno U., Strata G., Zucchi R. et al. Altered autonomic cardiac control in hypertrophic cardiomyopathy. Role of outflow obstruction and myocardial hypertrophy // Eur. Heart J. 1998. — Vol. 19. — P. 146−153.
- Simantirakis E. N., Kochiadakis G. E., Kanakaraki M. K. et al. Impact of chronic DDD pacing on time-domain indexes of heart rate variability in patients with hypertrophic obstructive cardiomyopathy. PACE 1999- 22: 1808−1813.
- Макаров JI. M. Холтеровское мониторирование. М.: «Медпрактика-М», 2008, — 456 с.
- Рябыкина Г. В., Соболев А. В. Мониторирование ЭКГ с анализом вариабельности ритма сердца. М.: «Медпрактика-М», 2005. — 222 с.
- Henry W., Gardin J., Ware J. Echocardiographic measurements in normal subjects from infancy to old age // Circulation. 1971. — Vol. 44. — P. 982−893.
- Umetani K., Singer D. H., McCraty R. et al. Twenty-four hour time domain heart rate variability and heart rate: relation to age and gender over nine decades // J.Am. Coll. Cardiol. 1998.-Vol. 313.-P. 593−601.
- Малкина Т. А. Клиническое значение вариабельности ритма сердца у больных с гипертрофической кардиомиопатией: Дис.. канд. мед. наук, М. 2007. — 155 с.
- Levin Е. R., Gardner D. G., Samson W. К. Mechanisms of disease: natriuretic peptides // N. Engl. Med. 1998. — Vol. 339. — P. 321−328.
- Vanderheyden M., Bartunek J., Goethals M. Brain and other natriuretic peptides: molecular aspects // Eur. J. Heart Fail. 2004. — Vol. 6. — P. 261−268.
- Valli N., Gobinet A., Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology // J. Lab. Clin. Med. 1999. — Vol. 134. — P. 437−444.
- Елисеев О. M. Натрийуретические пептиды. Эволюция знаний // Терапевтический архив. 2003. — № 9. — С. 40−45.
- Сафрыгина Ю. В. Клиническое значение определения содержания натрий-уретических пептидов в крови у больных гипертрофической кардиомиопатией при проспективном наблюдении: Дис.. канд. мед. наук, М. -2008. 118 с.
- Cowie М., Struthers A., Wood D. et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care // Lancet. 1997. — Vol. 350. -P. 1349−1353
- Maisel A., Krishnaswamy P., Koon J. Utility of B-natriuretic peptide as a rapid, point of care test for screening patients undergoing echocardiography to determine left ventricular dysfunction//Am. Heart J. -2001.-Vol. 141.-P. 367−374.
- Wang Т., Larson M., Levy D. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death // N. Engl. J. Med. 2004. — Vol. 350. — P. 655−663.
- Hartmann F., Packer M., Coats A. et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy // Eur. J. Heart Fail. 2004. — Vol. 6. — P. 343−350.
- Bassan R., Potsch A., Maisel A. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no-ST-segment elevation // Eur. Heart J. 2003. — Vol. 26. — P. 234−239.
- Maisel A., Krishnaswamy P., Nowak R. Rapid measurement of B-natriuretic peptide in emergency diagnosis of heart failure // N. Engl. J. Med. 2002. — Vol. 347. -P. 161−167.
- Groenning B. A., Nilsson J. C., Sondergaard L. el al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations // Am. Heart J. 2002. — Vol. 143. — P. 23−29.
- Kazanegra R., Cheng V., Garcia A. et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated hearts failure: a pilot study//J. Card. Fail. 2001. — Vol. 7.-P. 21−29.
- Yamamoto K., Burnett J., Jougasaki M. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy // Hypertension. 1996. — Vol. 28. — P. 988−994.
- Luchner A., Burnett J., Jougasaki M. et al. Evaluation of brain natriuretic peptide as a marker of left ventricular dysfunction and hypertrophy in the population // J. Hypertens. -2000.-Vol. 18.-P. 1121−1128.
- Van den Berg M., Tjeerdsma G., Jan de Kam P. et al. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure // Eur. J. Heart Fail. 2002. — Vol. 4. — P. 255−262.
- Ebato M., Nakamura Y., Ebato B. Plasma atrial and brain natriuretic peptide in patients with lone atrial fibrillation // Eur. Pleart. J. 1999. — Vol. 10 (suppl). — P. 219.
- Rossi A., Enriquez-Sarano M., Burnett J.C. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study // J. Am. Coll. Cardiol.-2000.-Vol. 35.-P. 1256−1262.
- Hall C. The value of natriuretic peptides for management of heart failure: current state of play // Eur. J. Heart Fail. 2001. — Vol. 3. — P. 395−397.
- Беленков Ю. H. Агманова Э. Т. Диастолическая функция сердца у больных с хронической сердечной недостаточностью и методы диагностики ее нарушений с помощью тканевой миокардиальной допплер-эхокардиографии // Кардиология. -2003.-№ 11.-С. 58−65.
- Lubien Е., DeMaria A., Krishnaswamy P. et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction // Circulation. 2002. — Vol. 105. — P. 595−601.
- Tschbpe C., Kasner M., Westermann D. et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements // Eur. Heart J. 2005. — Vol. 26. — P. 2277−2284.
- McCullough P. A., Nowak R. M., McCord J. et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study // Circulation. 2002. — Vol. 106. P. 416−422.
- Мак G. S., DeMaria A., Clopton P., Maisel A. S. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: Comparison with tissue Doppler imaging recording // Am. Heart J. 2004. — Vol. 148. P. 895−902.
- Osca PI., Zorio E., Martinez-Ortiz de urbina L. et al. Brain natriuretic peptide as an indicator of long term survival in isolated diastolic heart failure // Circulation. 2001. -Vol. 104 (suppl.).-P. И 501.
- Anand I., Fisher L., Chiang Y-T. et al. Changes in brain natriuretic peptide and norepinefrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Vd-HeFT)//Circulation.-2003.-Vol. 107.-P. 1276−1281.
- Richards A. M, Nicholls M. G., Espiner E. A. et al. B-type natriuretic peptide and ejection for prognosis after myocardial infarction // Circulation. 2003. — Vol. 10. -P. 2786−2792.
- Doust J., Pietrzak E., Dobson A., Glaszioup B. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review // Br. Med. J. 2005. — Vol. 330. — P. 625−634.
- Troughton R., Frampton C., Yandle Т., Espiner E., Niccholls M., Richards A. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations // Lancet. 2000. — Vol. 355. — P. 1126−1130.
- Yoshimura M., Mizino Y., Nakamuro M. et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure // Am. J. Med. 2002. -Vol. 12.-P. 716−720.
- The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evalutation of strategies for left ventricular dysfunction pilot study // Circulation. 2000. — Vol. 101. — P. 378−384.
- Luchner A., Burnett J., Jougasaki M. et al. Augmentation of the cardiac natriuretic peptides by beta-reception antagonism: evidence from a population-based study // J. Am. Coll. Cardiol. 1998. — Vol. 32. — P. 1839−44.
- Hasegawa K., Fujiwara H., Doyama K. et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy// Circulation. 1993. — Vol. 88. — P. 372−380.
- Takemura G., Fujiwara H., Mukoyama M. et al. Expression and distribution of atrial natriuretic polypeptide in human hypertrophic ventricle of hypertensive hearts and hearts with hypertrophic cardiomyopathy // Circulation. 1991. — Vol. 83. -P. 181−190.
- Briguori C., Betocchi S., Manganelli F. et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy // Eur, Fleart J. -2001. Vol. 22. -P. 1328−1336.
- Maeda K., Tsutamoto T., Wada A. ct al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction // Am. Heart J. 1998. — Vol. 135. — P. 825−832.
- Edwards B. S., Zimmerman R. S., Schwab T. R. et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor // Circ. Res. 1988. — Vol. 62. — P. 191−195.
- Kinnunen P., Vuolteenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching // Endocrinology. 1993. — Vol. 132. — P. 1961−1670.
- Edwards B. S., Ackermann D. M., Lee M. F. et al. Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure // J.Clin. Invest. 1988.-Vol. 81.-P. 82−86.
- Mykoyama M., Nakao K., Hosoda K. et al. Brain natriuretic peptide as a novel cardiac hormone in humans. J. Clin. Invest. 1991. — Vol. 87.-P. 1402−1412.
- Maron B. J., Venkatakrishna N. T., Zenovich A. G. et al. Usefulness of B-Type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy // Circulation. 2004. — Vol. 109. — P. 984−989.
- Esteban M. T., Thaman R., Barnes S. et al. Clinical and morphological determinants of N terminal pro-brain natriuretic peptide levels in hypertrophic cardiomyopathy // Eur. Heart J. 2003. — Vol. 24 (suppl.). — P. 560.
- Murakami Y., Shimada T., Inoue S. et al. New insights into mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy // Can. J. Cardiol. 2002. — Vol. 18. — P. 1294−300.
- Kitaoka H., Hitomi N., Yabe T. et al. Cardiovascular events and plasma atrial natriuretic peptide level in patients with hypertrophic cardiomyopathy // Am. J. Cardiol. -2001.-Vol. 87.-P. 1318−1320.
- Arteaga E., Araujo A., Buck P. et al. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy // Am. Heart J. 1998. — Vol. 150. -P.1228−1232.
- Araujo A., Arteaga E., Ianni B. et al. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy // Am. J. Cardiol. 2005. — Vol. 96. — P. 1563−1567.
- Sutton T. M., Stewart R. A., Gerber I. L. et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation // J. Am. Coll. Cardiol. -2003.- Vol. 41.-P. 2280−2287.
- Hunt P. J., Richards A. M., Nicholis M. G. et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (Nt-proBNP): a new marker of cardiac impairment // Clin. Endocrinol. 1997. — Vol. 47. — P. 1287−1296.
- Tsutamoto T., Wada A., Maeda K. et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure // Circulation. 1997. — Vol. 96. -P. 509−516.
- Vanderheyden M., Bartunek J., Goethals M. Brain and other natriuretic peptides: molecular aspects//Eur. J. Heart Fail. 2004. — Vol. 6.-P. 261−268.
- Levin E. R., Gardner D. G., Samson W. K. Mechanisms of disease: natriuretic peptides // N. Engl. Med. 1998. — Vol. 339. — P. 321−328.
- Maron B. J. Hypertrophic cardiomyopathy in childhood // Pediatr. Clin. North. Am.-2004.-Vol. 51 (5).-P. 1305−1346.
- Takagi E., Yamakado T., Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 1999. — Vol. 33 (1). -P. 206−211.
- Stewart J.T., McKenna W. J. Haemodynamic disorders: management and prognosis / In Cardiomyopathies. Realisation and expectations. Eds. Goodwin J. F. and Olsen E. G. -Springer-Vcrlag, Berlin Heidelberg, 1993.- P. 108−143.
- Maron B. J., Olivotto I., Spirito P. et al. Epidemiology of hypertrophic cardiomyo-pathy-related death. Revisited in a large non-referral-based patient population // Circulation. 2000. — Vol. 102. — P. 858−864.
- Cecchi F., Olivotto I., Betocchi S. et al. Registry for hypertrophic cardiomyopathy: a nationwide survey // Am. Heart J. 2005. — Vol. 150 (5). — P. 947−954.
- Keren A., Potekhin M., Khoury Z. et al. Morbidity and mortality during follow-up of patients with hypertrophic cardiomyopathy in the ISAAC registry // Eur. Heart J. -2005. Vol.26 (Abst. Suppl.). — P. 391.
- Cannan C. R., Reeder G. S., Bailey K. R. et al. Natural history of hypertrophic cardiomyopathy. A population based study, 1976 through 1990 // Circulation. 1995. -Vol. 92.-P. 2488−2493.
- Emote R., Yokota Y. et al. Prognosis in hypertrophic cardiomyopathy. Echocardiographic follow-up and histopathologic study // Jap. Circular. J. 1989. — Vol. 53 (9).-P. 1031−1044.
- Spirito P., Bellone P., Harris K.M. et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy // N. Engl. J. Med. 2000. -Vol. 342 (24).-P. 1778−178.
- Olivotto L., Maron M. S., Adabaget A. S. et al. HCM different in men and women? Impact of gender on clinical presentation and outcome // Eur. Heart J. 2005. — Vol. 26 (Abstr. Suppl.).-P. 389.
- Esteban M. Т., Ward D. et al. Hypertrophic cardiomyopathy in adolescence: mode of presentation, gender differences and disease progression // Eur. Heart J. 2005. -Vol. 26. — (Abstr. Suppl.). — P. 394.
- Cecchi F., Olivotto I., Montereggi A. et al. Hypertophic cardiomyopathy in Tuscani: clinical course and outcome in an unselected regional population // J. Am. Coll. Cardiol. -1995. Vol. 26. — P. 1529−1536.
- Higashikawa M., Nakamura Y., Yoshida M. et al. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation // Jpn. Circ. J. 1997. — Vol. 61. — P. 673−681.
- Maron B. J., Olivotto I., Bellone P. et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 2002. — Vol. 39. — P. 301−307.
- Spirito P., Lakatos E., Maron B. J. Degree of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy and chronic atrial fibrillation // Am. J. Cardiol. 1992. -Vol. 69.-P. 1217−1222.
- Blanchard D. G., Ross J. Hypertrophic cardiomyopathy: prognosis with medical or surgical therapy // Clin. Cardiol. 1991. — Vol. 14. — P. 11−19.
- Spirito P., Maron B. J., Bonow R. O. et al. Occurrence and significance of progressive left ventricular wall thinning cavity dilatation in hypertrophic cardiomyopathy // Am. J. Cardiol. 1987. — Vol. 60. — P. 123−129.
- Шапошник И. И., Шапошник О. Д. Развитие признаков дилатационной кардиомиопатии у больных необструктивной гипертрофической кардиомиопатией // Терапевтический архив. 1992. — Vol. 11. — Р. 125−126.
- Pieroni М., Chimenti С., Verando R. et al. Myocardial inflammation in hypertrophic cardiomyopathy patients presenting acute clinical deterioration // Eur. Heart J. 2006. -Vol. 27 (Abstr. Suppl.). — P. 544.
- Maron B. J., Shirani J., Poliac L.C. et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles // JAMA. 1996. — Vol. 276. — P. 199−204.
- Мазур H. А. Внезапная смерть (стратификация риска и профилактика). -М.: Медпрактика-М, 2003. 24 с.
- Cecchi F., Maron B.J., Epstein S. E. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest // J. Am. Coll. Cardiol.- 1989.-Vol. 13.-P. 1283−1288.
- Elliott P. M., Poloniecki J., Dickie S. et al. Sudden death in hypertrophic cardiomyopathy. Identification of high risk patients // J. Am. Coll. Cardiol. 2000. -Vol. 36.-P. 2212−2218.
- Hess O. M. Risk Strafication in Hypertrophic Cardiomyopathy // J. Am. Coll. Cardiol.-2003. Vol. 42 (5). — P. 880−881.
- Adabag A. S., Casey S. A., Maron B. J. Sudden death in hypertrophic cardiomyopathy. Patterns and prognostic significance of tachyarrhythmias on ambulatory holter ECG // Circulation. 2002. — Vol. 106. — P. II 710.
- Monserrat L., Elliott P. M., Sharma S. et al. Non-Sustained ventricular tachycardia in hypertrophic cardiomyopathy: a marker of sudden death risk in young patients // J Am Coll Cardiol. 2003. — Vol. 42. — P. 873−879.
- Stewart J. T., McKenna W. J. Haemodynamic disorders: management and prognosis / In Cardiomyopathies. Realisation and expectations. Eds. Goodwin J. F. and Olsen E. G. -Springer-Verlag Berlin Heidelberg, 1993. P. 108−143.
- McKenna W., Harris L., Deanfield J. Syncope in hypertrophic cardiomyopathy // Br. Heart J. 1982.-Vol. 47.-P. 177−179.
- Dilligan D .M., Nihayannopoulos P., Chan W. L., et al. Investigation of a hemodynamic basis for syncope in hypertrophic cardiomyopathy: use of a head-up tilt test // Circulation. 1992. — Vol. 85. — P. 2140−2148.
- Manganelli F., Betocchi S., Loai M. A. et al. Influence of left ventricular cavity size on clinical presentation in hypertrophic cardiomyopathy // Am. J. Cardiol. 1999. -Vol. 88.-P. 547−551.
- Tamura M., Flarada K., Ito T. et al. Abrut aggravation of atrioventricular block and syncope in hypertrophic cardiomyopathy // Arch. Dis. Child. 1995. — Vol.73. P. 536−537.
- Maki S., Ikeda H., Muro A. et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy // Am. J. Cardiol. 1998. — Vol. 82. — P. 774−778.
- Olivotto I., Maron B. J., Montereggi A. et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 1999. — Vol. 33. — P. 2044−2051.
- Ciampi Q., Betocchi S., Lombardi R. et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 2002. — Vol. 40. — P. 278−284.
- Maron B. J., Piccininno M., Casey S. A. et al. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy // Am. J. Cardiol.- 2003. Vol. 91. -P. 626−628.
- Elliott P. M., Gimeno B. J., Marion N. G. et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy // Lancet. 2001. — Vol. 357. — P. 420−424.
- Lown B., Verrrier R. L. Neuronal activity and ventricular fibrillation // N. Engl J. Med. 1976. — Vol. 294. — P. 1165−1170.
- Goodwin J. F. Prospects and predictions for the cardiomyopathies // Circulation. -1974.-Vol. 50.-P. 210−219.
- Blaufuss A. H., Laks M. M., Garner D. et al. Production of ventricular hypertrophy simulating idiopathic hypertrophic subaortic stenosis (IHSS) by subhypertensive infusion norepinefrine in the conscious dog // Clin. Res. 1975. — Vol. 23. — P. 77a.
- Банержи А. Медицинская статистика (перевод под редакцией В.П.Леонова).-Москва, Практическая медицина, 2007. 287 с.
- Araujo A. Arteaga Е., Ianni В. et al. Relationship between outflow obstruction and left ventricular functional impairment in hypertrophic cardiomyopathy: a Doppler echocardiographic study // Eur. Heart J. 2006. — Vol. 27. (Abstr. Suppl.). — P. 541.
- Kollias G., Stefanidis A., Koutroulis G. et al. Left-ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Echocardiographic characteristics and clinical significance // Eur. Heart J. 2003. — Vol. 24. — P. 559.
- Шапошник И. И., Богданов Д. В., Фёдоров Д. В. и др. Вопросы длительного наблюдения больных кардиомиопатиями // Актуальные вопросы внутренней патологии: сб. науч. тр. Челябинск, 2002. — С. 215−219.
- Boriani G., Rapezzi С., Biffi М. et al. Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy // J. Cardiovasc. Electrophysiol. -2002.-Vol. 13. P. 954.
- Roberts R., Sigwart U. Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy // Circulation. 2005. — Vol. 12. — P. 293−296.
- Maron B. J., Mathenge R., Casey S. A. et al. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities // J. Am. Coll. Cardiol. 1999. -Vol. 33.-P. 1590−1595.
- Maron B. J., Shen W.-K., Link M.S. et al. Efficacy of implantable cardioverter-defibrillator for the prevention of sudden death in patients with hypertrophic cardiomyopathy // N. Engl. J. Med. 2000. — Vol. 342. — P. 365−373.
- Cohen L. S., Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade // Circulation- 1967.-Vol. 35. P.847−851
- Sherrid M. V., Pearle G., Gunsburg D. Z. et al. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy // Circulation. 1998. — Vol. 97. -P. 41−47.
- Stenson R. E., Flamm M. D., Harrison D. C. et al. Hypertrophic subaortic stenosis: clinical and hemodinamic effect of long term propranolol therapy // Am. J. Cardiol. -1973, — Vol. 31.-P. 763−773.
- Cuccurullo F., Mezzetti A., Lapena D. et al. Mechanism of isoproterenol-nduced angina pectors in patients wth hypertrophic cardiomyopathy and normal coronary arteries // Am. J. Cardiol. 1987. — Vol. 60. — P. 667−673.
- Sharma S., Elliott P., Whyte G. et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy // Am. J. Cardiol. 2000. — Vol. 86. — P. 162−168.
- Louie E. K., Edwards L. C. Hypertrophic cardiomyopathy // Prog. Cardiovasc. Dis. -1994.-Vol. 36. P. 275−308.
- Gleichmann U., Seggewiss H. Clinical picture and therapy of hypertrophic cardiomyopathy // Med. Klin. 1998. — Vol. 93. — P. 260−267.
- Коровина E. П. Бета-адреноблокаторы и антагонисты кальция при гипертрофической кардиомиопатии // Клин. Мед. 1998. — Vol.12. — С. 30−35.
- Bruetsaert D. L., Sys S. U., Gillebert Т. С. et al. Diastolic failure: pathophysiology and therapeutic complications // J. Am. Coll. Cardiol. 1993. -Vol. 22.-P. 318−325.
- Ostman-Smith I., Wettrell G., Riesenfeld T. A cohort study of chaldhood hypertrophic cardiomyopathy. Improved survival following high-dose beta-adrenoceptor antagonist treatment // J. Am. Coll. Cardiol. 1999. — Vol. 34. — P. 1813−1822.
- Ostman-Smith I. Regression of cardiac hypertrophy achieved by high dose propranolol treatment in children and adults with hypertrophic cardiomyopathy // Br. Heart J. 1'991.-Vol. 66.-P. 76.
- Nora M., Zipes D. P. Empric use of amiodarone and sotalol // Am. J. Cardol. -1993.-Vol. 72 (16).-P. 62F-69 °F.
- Tendera M., Wycisk A., Schneeweis A. et al. Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy // Cardiology. 1993. -Vol. 82 (5).-P. 335−342.
- Джанашия П. X., Назаренко В. А., Николенко С. А. и др. Гипертрофическая кардиомиопатия: уч. пособие. Москва, 2007.- 63 с.
- Rosing D. R., Condit J. R., Maron В. J. et al. Verapamil therapy. A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: effects of long-term administration // Am. J. Cardiol. 1981. — Vol. 48. — P. 545−553.
- Gistri R., Cecchi F., Choudhury L. et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy //Am. J. Cardiol.- 1994.- Vol. 74. P. 363- 368.
- Epstein S. E., Rosing D. R. Verapamil: its potential for causing serious complication in patients with hypertrophic cardiomyopathy // Circulation. 1981. — Vol. 64. — P. 437−441.
- Gilligan D. M., Chan W. L., Joshi J. et al. A double-blind, placebo-controlled crossover trial of nodalol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. 1993. — Vol. 21. — P. 1672−1679.
- Toshima H., Koga Y., Nagata H. et al. Comparable effects of oral diltiazem and verapamil in the tratment of hypertrophic cardiomyopathy. Double-blind crossover study // Jpn. Heart J. 1986. — Vol. 27. — P. 701−715.
- Morrow A. G., Reitz B. A., Epstein S. E. et al. Operative treatment in hypertrophic subaortic stenosis // Circulation. 1975. — Vol. 52. — P. 88−102.
- Merril W. H., Friesinger G. C., Graham T. P. Jr. et al. Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy // Ann. Thorac. Surg. -2000. Vol. 69. — P. 1732−1735.
- Theodoro D. A., Danielson G. K., Feldt R. H., Anderson B. J. Hypertrophic obstructive cardiomyopathy in pediatric patients. Results of surgical treatment //J. Thorac. Cardiovasc. Surg. 1996. — Vol. 112. — P. 1589−1597.
- Robbins R. C., Stinson E. B. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy // J. Thorac. Cardiovasc. Surg. -1996.-Vol. 111.-P. 586−594.
- Schulte H. D., Borisov K., Gams E. et al. Management of symptomatic hypertrophic obstructive cardiomyopathy long-term results after surgical therapy // J. Thorac. Cardiovasc. Surg. — 1999. — Vol. 47. — P. 213−218.
- Seiler C., Hess О. M., Schoenbeck M. et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study // J. Am. Coll. Cardiol. 1991. — Vol. 17. — P. 634−642.
- Бокерия Jl. А., Борисов К. В., Синёв А. Ф. и др. Хирургическая коррекция гипертрофической обструктивной кардиомиопатии у детей при помощи оригинального способа // Грудная и сердечно-сосудистая хирургия. 2003. — № 2. — С. 22−28.
- Nishimura R. A., Trusty J. M., Hayes D. L. et al. Dual-chamber pacing for hypertrophic cardiomyopathy. A randomized, double-blind, crossover trial // J. Am. Coll.Cardiol. 1997. — Vol. 29. — P. 435−441.
- Faber L., Meissner A., Ziemssen P., Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients // Heart. 2000. — Vol. — 83. — P. 326−331.
- Lakkis N. M., Nagueh S. F., Dunn J. К. et al. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. One-year follow-up // J. Am. Coll. Cardiol. -2000. Vol. 36. — P. 852−855.
- Kuhn 11. Gietzen F. II., Leuner C. et al. Transcoronary ablation of septal hypertrophy (TASH). A new treatment option for hypertrophic obstructive cardiomyopathy// Z. Kardiol. 2000. — Vol. 89 (Suppl. 4). — P. IV41−54.
- Frank M. J., Abdulla A. M., Watkins L. O. et al. Long-term medical management of hypertrophic cardiomyopathy: usefullness of propranolol // Eur. Heart J. 1983. — Vol. 4 (suppl. F). — P. 115−164.
- Udelson J. E., Bonow R. O., Ogara P. T. et al. Verapamil presents slent myocardial perfusion abnormalities durng exercise in asymptomatic patients with hypertrophic cardiomyopathy // Circulation. 1989. — Vol. 79. — P. 1052−1060.
- Sugihara H., Taniguchi Y., Ito K. et al. Effect of diltiazem on myocardial abnormalites durng exercise in patients with hypertrophic cardiomyopathy // Ann. Nucl. Med. 1998. — Vol. 12 (6). — P. 349−354.
- Pacileo G., Cristofaro M., Russo M.G. et al. Hypertrophic cardiomyopathy n pediatric patients: effect of verapamil on regional and global left ventricular diastole function // Can. J. Cardiol. 2000. — Vol. 16 (2).- P. 146−152.
- Pellcia F. Hypertrophic cardiomyopathy: long-term effects of propranolol versus verapamil in preventing sudden death in «low-risk» patients // Cardiovasc. Drugs Ther. -1990.-Vol. 4.-P. 1515−1518.
- Сторожаков Г. И., Кисляк О. А. Селиванов А. И. и соавт. Гипертрофическая кардиомиопатия // Кардиология. 1995. — Том 35, № 6. — С. 78−85.
- Christensen G., Aksnes G., Ilebekk A. et al. Release of atrial natriuretic factor during selective cardiac alpha- and beta-adrenergetice stimulation, intracoronary Ca2+ infusion, and aortic constriction in pigs//Circ. Res.-1991.-Vol. 68.-P. 638−644.
- Yoshimoto T., Naruse M., Tanabe A. et al. Potentiation of natriuretic peptide action by the beta-adrenergetic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism // Endocrinology. 1998. — Vol. 139. — P. 81−88.